What Does Quality of Care Mean in Lower-Grade Glioma Patients: A Precision Molecular-Based Management of the Tumor or an Individualized Medicine Centered on Patient’s Choices?

Frontiers in Oncology

Luc Taillandier³  Tiphaine Obara³  Hugues Duffau⁴ 

[1] Centre de Recherche en Automatique Nancy France - UMR 7039 - BioSiS Department, Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France;Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France;Neurology Departement, Neurooncology Unit, CHRU, Nancy, France;Team “Plasticity of Central Nervous System, Stem Cells and Glial Tumors”, National Institute for Health and Medical Research (INSERM), U1191 Laboratory, Institute of Functional Genomics, University of Montpellier, Montpellier, France;

关键词: glioma;    quality of life;    evidence-based medicine;    precision medicine;    awake surgery;    chemotherapy;   

DOI  :  10.3389/fonc.2021.719014

来源: DOAJ

【 授权许可】

Unknown